Search for content, post, videos

Sobi sells Priority Review Voucher to AstraZeneca

Sobi Research

Swedish Orphan Biovitrum has entered into an agreement to sell a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) to AstraZeneca for a total cash consideration of USD 95 million.

A PRV entitles the holder to FDA priority review of a single New Drug Application or Biologics License Application, which reduces the target review time and may potentially lead to an expedited approval.

The PRV was acquired as part of the acquisition of the emapalumab related business from Novimmune in July 2019. The transaction is subject to customary regulatory approval.